Quick Takeaways:
- Elanco Animal Health has secured APVMA approval for Advocate Ultra Chew (lotilaner, moxidectin, praziquantel, pyrantel) in Australia, with launch slated for April 2026. The product, known as Credelio Quattro in the US, marks its first international expansion
- Delivered as a once-monthly chewable, Advocate Ultra Chew offers broad-spectrum protection against fleas, ticks (including paralysis ticks), heartworm, and intestinal worms, including tapeworms. Notably, it is the only all-in-one product covering zoonotic tapeworms like Echinococcus granulosus, addressing key health risks for both pets and owners
- Designed for dogs and puppies ≥8 weeks (≥2 kg), the therapy has demonstrated safety across breeds, including heartworm-positive and avermectin-sensitive dogs. By combining four established actives into a single dose, Elanco aims to set a new standard in parasite protection while strengthening its trusted Advocate brand in Australia
Why It Matters?
APVMA approval gives Elanco a timely first international expansion for Credelio Quattro under the Advocate franchise, letting it leverage strong brand equity to capture share in Australia’s highly competitive, vet‑driven parasiticide market.
By offering the only all‑in‑one monthly chew that also covers zoonotic tapeworms such as Echinococcus granulosus and paralysis ticks, Elanco can push a “single‑tablet standard of care” narrative with veterinarians, reinforcing differentiation on both spectrum and public‑health relevance.
Source: Elanco
